Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca’s Ardea Acquisition: A Rich Deal Spurred By Phase III Gout Candidate

This article was originally published in The Pink Sheet Daily

Executive Summary

The $1.26 billion buyout comes as the pharma is looking to bolt-on acquisitions to help offset recent late-stage pipeline disappointments and sees Ardea’s lesinurad as a potential improvement in gout therapy, an estimated $2 billion global market.

You may also be interested in...



Deal Watch: AbbVie, arGEN-X To Explore Immuno-Oncology According To GARP

Also during a busy two-week stretch, AbbVie signs a partnership to co-develop drug conjugate products with CytomX, acquires privately held Stemcentrx, and agrees to a broad-based five-year cancer research collaboration with University of Chicago. Sanofi makes formal bid to acquire Medivation, which is rejected.

Ironwood Buys AstraZeneca's Zurampic As Ideal Linzess Complement

What was AstraZeneca's trash is now Ironwood's treasure, as it pays $100m up front, along with milestones and royalties, to acquire gout drug approved in December but not yet launched.

AstraZeneca's Hudson Optimistic On Return To Growth In 2017

US President Paul Hudson talked in an interview at the J.P. Morgan Healthcare conference about the company’s budding oncology portfolio, upcoming launches and growing optimism as the 2017 return-to-growth goal approaches.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel